Neurophysiological studies have shown that serotonergic ligands that bind to 5-HT1A, 5-HT7 and 5-HT4 serotonin receptors in the brainstem have beneficial effects on respiratory neurons during opioid-induced respiratory depression. The effect of these ligands on respiratory function and pulmonary performance has not been studied. We therefore 
Introduction
Opioids cause respiratory depression, a particular problem when they are used as analgesics (26; 27) and when they are used to immobilize wild herbivores (7; 16; 40) . This respiratory depression may cause hypoxic damage to vital organs (31) . Opioids affect the respiratory system mainly through their action on µ-opioid receptors on respiratory neurons in the pre-Bötzinger complex (14; 25) , a collection of neurons in the brainstem that generate respiratory rhythm (39) . The complex depends on neurotransmitters, including serotonin, for the modulation of respiratory rhythm (29) .
Serotonin enhances activity in respiratory neurons through its action on 5-HT1A, 5-HT4 and 5-HT7 serotonin receptors (33) . The contrasting actions of opioids and serotonin on respiratory neurons allows for the possibility that serotonergic ligands could alleviate the depressive action of opioids on these neurons.
That possibility has been realized in recent neurophysiological investigations. The serotonergic ligands 8-OH-DPAT, an agonist at 5-HT1A and 5-HT7 receptors, and buspirone, a partial agonist at the 5-HT1A receptor, reversed morphine-induced depression of respiratory neurons in anaesthetized rats (37) . BIMU8, an agonist at the 5-HT4 receptor, reversed fentanyl-induced depression of respiratory neurons, importantly without reversing analgesia, in anaesthetized rats (25) . However, although measurements of neuronal activity may reveal the potential of serotonergic ligands to influence respiration, determining whether such ligands actually improve respiratory function requires measurement of pulmonary performance in the whole animal. Also since serotonin receptors are widely distributed throughout the body (15) , even if serotonergic ligands improve pulmonary performance, they may generate adverse effects elsewhere in the body which may negate that benefit. If they are to be used to alleviate opioid-induced respiratory depression, they should not counteract the intentional effects of the opioids.
Mortality and morbidity resulting from the respiratory depression are major problems when opioids are used to immobilize animals. We therefore set out to assess whether the serotonergic ligands 8-OH-DPAT and zacopride could be employed to reverse such depression, using the physiologically-relevant index of pulmonary function, namely arterial blood gas status. Since opioids are used therapeutically much more often to immobilize ungulates than to immobilize small animals, we used goats as an experimental animal. As our opioid, we used the pharmacological agent preferred for immobilization of ungulates, namely the morphine derivative etorphine, a potent agonist of µ-opioid receptors. Concomitantly, we needed to establish if the serotonergic ligands would influence etorphine-induced catatonia and sedation in the goats. We hypothesized that 8-OH-DPAT, an agonist at 5-HT1A and 5-HT7 receptors, and zacopride, an agonist at 5-HT4 receptors and an antagonist at 5-HT3 receptors, would reverse opioid-induced respiratory depression and hypoxia without reversing the opioid-induced catatonic immobilization and sedation. Although our investigation was targeted to opioid-induced immobilization, its outcomes clearly would have implications for respiratory depression in patients under opioid analgesia.
6

Methods
Animals
Eight healthy adult female boer goats (Capra hircus), weighing 40±9 kg (mean ± SD), were used. They were housed in climatically-controlled indoor pens in Johannesburg, at an altitude of 1753 m, on a 12 hour light/dark cycle. They had water ad libitum and were fed on hay and sheep concentrate pellets. The procedures were approved by the University of the Witwatersrand's Animal Ethics Screening Committee (clearance 2004/31/5).
Surgery
After veterinary inspection, anesthesia was induced with an I.M. injection of 2.5mg.kg The left lateral aspect of the neck was shaved and prepared aseptically for surgery. The left carotid artery was translocated surgically to a subcutaneous tunnel according to the modified transposition technique described by Orsini & Roby (32) , to allow for subsequent repetitive arterial catheterization in conscious animals. After surgery a pressure bandage was placed over the site for 24 hours. The animals were given a month to recover before the experimental trials commenced. 
Drugs
Experimental procedure
The experiment consisted of three trials in which each goat received etorphine + water (control), etorphine + zacopride, and etorphine + 8-OH-DPAT, in a random order, at weekly intervals. The goats were weighed two days before each trial and were starved for 24 hours before the trial to reduce the risk of bloating and regurgitation of ingesta. On the day of the trial, the neck, over the translocated artery, and ears were shaved and 
Data analysis
We used GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, United States of America) and Statistica 99 edition (StatSoft, Tulsa, United States of America) for statistical analyses. All results were reported as mean ± SD, and a P < 0.05 was considered statistically significant. The areas between the response curves (over time) to etorphine + water, etorphine + zacopride, and etorphine + 8-OH-DPAT were calculated for respiration rate, heart rate, hemoglobin oxygen saturation and mean arterial pressure, for the first 6 min interval (pre-etorphine + water/ligand administration), the first, second, and third 10 min intervals, and the entire 30 min, after etorphine + water/ligand administration, and the 10 min after diprenorphine administration. A oneway ANOVA followed by a Student Neuman Keuls (SNK) post-hoc test was used to test for differences between these areas, and also for differences in the times to recumbency. Tb is the body temperature taken as per rectum. We assumed that the partial pressure of CO 2 in the alveoli was equal to the arterial partial pressure of CO 2 (13; 31; 35) . restless and we were unable to accurately assess any cardio-respiratory variables.
Results
Immobilization
Respiratory rate
Etorphine administration caused a significant (Student's paired t-test, P = 0.013) decrease in respiratory rate: before etorphine + water were injected the respiratory rate was 27±9 
Percentage hemoglobin oxygen saturation
Etorphine administration resulted in a significant (Student's paired t-test, P < 0.0001) decrease in the saturation of arterial hemoglobin with oxygen over the 30 min of immobilization (Fig. 2) . The decrease in saturation was greatest in the first 10 min of the immobilization. Saturation before etorphine administration was 96±3 % (n = 8) and dropped to as low as 75±7 % (n = 8) after 4 min, with a gradual increase thereafter over time. After diprenorphine injection the saturation returned to near pre-injection values (Student's paired t-test, P = 0.5). Although saturations significantly decreased after the administration of etorphine + zacopride (Student's paired t-test, P = 0.0025) and etorphine + 8-OH-DPAT (Student's paired t-test, P = 0.0002), both zacopride and 8-OH-DPAT attenuated the etorphine-induced decrease in saturation. Over the entire immobilization period, saturation in the goats that received etorphine + zacopride was significantly (F = 7.18, P < 0.05) higher than that evident when they received etorphine + water. Saturation in the goats that received etorphine + 8-OH-DPAT was significantly (F = 10.76, P = 0.0015) higher than that when they received etorphine + water only over the first 10 min interval after administration. Zacopride (Student's paired t-test, P = 0.75) did not alter the return of saturations to pre-injection levels after diprenorphine administration, whereas saturation of the goats that received 8-OH-DPAT + etorphine remained moderately depressed (Student's paired t-test, P = 0.02). Heart rate Figure 6 shows the effects of administrating etorphine, with and without serotonergic ligands, on heart rate. Heart rate was 67±5 beats.min -1 (n = 8) before etorphine administration. Over the time course of the immobilization, heart rate decreased following etorphine administration, whether or not the ligands were co-administered. In contrast to its effect on respiratory variables, etorphine administration did not affect heart rate immediately. Heart rate was unchanged for at least the first 8 min after etorphine administration. Thereafter, the decline in heart rate was attenuated by co-administration of zacopride, but accentuated by co-administration of 8-OH-DPAT. After the second 10 min interval, heart rate was significantly (F (2,7) = 0.33, P < 0.001) decreased following 8-OH-DPAT co-administration, and increased (F (2,7) = 0.33, P < 0.01) following zacopride co-administration, compared to the heart rates which followed etorphine coadministration with water. In the etorphine + water and etorphine + zacopride trials the heart rates returned to pre-injection rates after diprenorphine administration, whereas the heart rates in the etorphine + 8-OH-DPAT trial remained significantly (Student's paired ttest, P < 0.0001) lower than the pre-injection rates.
Partial pressure of oxygen
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Discussion
At a dose at which it immobilized goats, the opioid etorphine caused marked respiratory depression. Symptomatically, this depression was evident as a decrease in respiratory rate to about half of the rate before etorphine administration. The respiratory rate remained low throughout the immobilization period, but, alone, it did not reveal the respiratory status of the animals. Directly after the administration of etorphine, and up until 10 min after injection, respiratory depression was the most severe; the animals became clinically hypoxic, taken as PaO 2 < 60mmHg and percentage arterial hemoglobin saturation < 85% (Fig. 4) . The main beneficial effect of 8-OH-DPAT was on the pulmonary circulation; it improved diffusion, as indicated by the restoration of normal differences between alveolar and arterial partial pressures of oxygen (Fig. 5) , presumably by improving ventilation-perfusion ratios. Zacopride also partially restored the alveolararterial gradient but its effect was not as great as that of 8-OH-DPAT. In addition to the deleterious effects on the respiratory system, the opioid also affected the cardiovascular status of the goats, by inducing bradycardia and transient hypertension (Figs 6 and 7 ).
The serotonergic ligands influenced those cardiovascular effects too. Zacopride abolished the hypertension whereas 8-OH-DPAT transiently exacerbated the etorphine-induced biphasic changes in mean arterial pressure (Fig. 7) . Similarly, zacopride reduced, and 8-OH-DPAT enhanced, the bradycardia (Fig. 6 ). increased the frequency of phrenic nerve discharges in anaesthetized cats, but higher doses (50 and 90µg.kg -1 ) suppressed phrenic nerve discharges. In a similar and more recent study (34) , phrenic nerve discharges were decreased even when 20 µg.kg -1 of 8-OH-DPAT was injected intravenously in cats. We used a much higher dose (500 µg.kg 
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Opioids are used in veterinary practice and game management to immobilize mammals (16; 40) . They induce a catatonic immobilization by acting on localized areas in the central nervous system (41) . In the rat, at least, the most prominent of these areas are the nucleus raphe pontis (1; 5; 6; 41; 44) and the nucleus accumbens (12) . Both these nuclei contain serotonergic receptors (44) , and serotonin enhances opioid-induced catatonia (6; 12; 44) . To the best of our knowledge, no-one has identified which serotonin receptors are involved in such enhancement. We have shown that both zacopride and 8-OH-DPAT enhanced opioid-induced catatonia, in that both reduced time to recumbency in our goats, when co-administered with etorphine. Subsequently, though zacopride somewhat reduced, rather than enhanced, the sedative effects of etorphine. This finding may be explained if zacopride, through its 5-HT 3 antagonistic effects, reversed the effects of kappa opioid receptors (18) , thereby resulting in a decrease in opioid-induced hypotonic immobility (9) . It would seem that more than one serotonergic receptor mediates the enhancement of opioid-induced immobilization, but because these ligands each act on two 5-HT receptor types, we are unable to draw any conclusions as to which receptors are involved. We do know that neither ligand, at least at the dose we used, brought about immobilization in its own right.
We postulate that the key serotonergic receptors involved in combating opioid-induced respiratory depression, at least in goats, are the 5-HT4 and 5-HT7 receptors, but positive identification of the receptors will require further studies with specific ligands. However, until we also know what serotonergic receptor is responsible for improving opioidinduced catatonic immobilization, we should not conclude that a specific receptor ligand 26 would be the most putative therapeutic agent to improve both immobilization and respiratory welfare.
In summary we have shown that the serotonergic ligands improve blood oxygenation, in goats with respiration depressed by opioid administration, both by improving ventilation and by improving oxygen diffusion, we believe, by improving pulmonary perfusion.
Further studies are required to identify the mechanisms involved, and will require measurements of pressures and flows in the respiratory system. Also, although our focus has been reduction of morbidity and mortality resulting from respiratory depression in animals immobilized by opioid administration, and although extrapolation between species should be made with caution, we feel that we also have provided more evidence that serotonergic ligands might be useful in reversing respiratory depression in patients under opioid analgesia or anesthesia, without interfering with the intentional effects of the opioids. 
